CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Pfizer Inc is developing CP-751871, a fully human IgG2 antibody specific for the type I insulin-like growth factor receptor for the potential treatment of various cancers and rheumatoid arthritis. A phase Ib/II clinical trial of CP-751871 in combination with paclitaxel and carboplatin in patients with advanced NSCLC is underway.

Original languageEnglish (US)
Pages (from-to)299-304
Number of pages6
JournalCurrent Opinion in Molecular Therapeutics
Volume9
Issue number3
StatePublished - Jun 1 2007

Fingerprint Dive into the research topics of 'CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer'. Together they form a unique fingerprint.

Cite this